CaeTrader CaeTrader
Vertex VRTX Biotech
43.2 Score +11.3 (24h) +19.5 (7d)
Updated 0m ago
Price History
Candle
RSI (14)
MACD (12, 26, 9)
ADX (14)

Score Guide

0 Bearish 50 Neutral 100 Bullish
3 Bullish2 Bearish2 Neutral

Analyst Ratings

81%
32 analysts
Buy
81%
Hold
16%
Sell
3%
Consensus: Buy → stable

Key Financials

Price $425.56
Mkt Cap $108.25B
P/E 27.8
Beta 0.3
EPS $15.30
Div Yield N/A
Low $330 Mean $548 High $641
Current: $425.56
Latest News
Zacks · 2h ago +0.94
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
Zacks · 7h ago 0.01
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Simply Wall St. · 1d ago -0.01
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) came out with its first-quarter results last week, and we wanted to...
Simply Wall St. · 2d ago -0.83
Is It Too Late To Consider Vertex Pharmaceuticals (VRTX) After Recent Share Price Weakness
Wondering if Vertex Pharmaceuticals at around US$424 per share is still a solid opportunity or if the easy gains are behind it? This article focuses squarely on what the current price might represent for you. The stock has had a mixed run, with a 1.3% decline over the last week, a 3.3% decline over the last month, a 6.1% decline year to date and a 5.7% decline over the past year, set against longer term returns of 23.1% over three years and 99.2% over five years. Recent coverage of Vertex...
Motley Fool · 2d ago 0.05
Is This Millionaire-Maker Biotech Stock a Buy Right Now?
The market wasn't impressed by its latest quarterly update.
Investor's Business Daily · 2d ago -0.60
Vertex Dips On Mixed First-Quarter Report; But There's A Silver Lining
Vertex stock skidded Tuesday on a mixed first-quarter report, but analysts remain more interested in the company's R&D plans.
MT Newswires · 3d ago +0.89
Vertex Pharmaceuticals Confident in Emerging Renal Franchise, Oppenheimer Says
Vertex Pharmaceuticals' (VRTX) management remains confident in its emerging renal franchise, suggest
Zacks · 3d ago +0.94
VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth
Vertex tops Q1 estimates as revenues climb 8% on strong CF drug demand and new product gains. Its pipeline has advanced and its 2026 guidance reaffirmed.
Zacks · 3d ago +0.88
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MT Newswires · 3d ago -0.07
US Equity Futures Gain Pre-Bell as Traders Keep Eye on Potential Re-Escalation of Middle East Hostilities
US equity futures were higher pre-bell Tuesday as traders kept a close watch on the potential re-esc